6月2日 - ** 药物开发商Rezolute（RZLT.O）的股价在盘前交易中上涨4.7%，至3.78美元
** 该公司表示，在针对肿瘤性高胰岛素血症患者进行的ersodetug药物晚期临床试验中，取得了积极的中期结果。肿瘤性高胰岛素血症是一种罕见疾病，其特征是血糖严重偏低
** 公司表示，8名受试者中有6人已达到主要目标，即静脉葡萄糖需求量较基线水平至少降低50%
** RZLT目前已完成计划研究样本量（16名受试者）的一半招募
** 截至上一交易日收盘，该股年内累计涨幅达53%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.